Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.33 |
| ▸ | PDE1A | P54750 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797534 | 0.91 | PDE1B (0.36) | LRRK2PDE1BEZH2PDE1CPDE1A | |
| SCHEMBL5844055 | 0.91 | PDE1B (0.36) | LRRK2PDE1BEZH2PDE1CPDE1A | |
| SCHEMBL5845474 | 0.85 | HPGDS (0.38) | PDE1BPDE1CPDE1AHPGDS | |
| SCHEMBL6800033 | 0.82 | GRM5 (0.38) | PDE1BHPGDS | |
| SCHEMBL6792201 | 0.81 | HSP90AA1 (0.41) | PDE1BPDE1CPDE1A | |
| SCHEMBL6799142 | 0.80 | LRRK2 (0.36) | LRRK2PDE1BEZH2 | |
| SCHEMBL6799139 | 0.80 | LRRK2 (0.36) | LRRK2PDE1BEZH2 | |
| SCHEMBL6797091 | 0.80 | MCHR1 (0.35) | PDE1BPDE1CPDE1AHPGDS | |
| SCHEMBL6795536 | 0.80 | PDE1B (0.37) | PDE1BPDE1CPDE1AHPGDS | |
| SCHEMBL6797756 | 0.79 | HPGDS (0.35) | LRRK2PDE1BHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | LRRK2 1455/4885PDE1B 2331/4885PDCD1 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.